Key facts
- Alpha Biopharma’s last known valuation is $595.0M (Apr 2022).
- It has raised $123.9M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Qiming Venture Partners, Hangzhou Tigermed Consulting Company, LYZZ Capital, TF Capital, Tibet Rhodiola Pharmaceutical Holding.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Alpha Biopharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Alpha Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Alpha Biopharma
Developer of drugs and clinical products designed to address unmet clinical needs. The company's products include drugs and therapies that target and treat non-small cell lung cancer patients with central nervous system metastases, enabling its clients to receive cancer-related drugs.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2017
- Employees
- 3
- Website
- alphabiopharma.com/
- Ownership
- Privately Held (backing)
Alpha Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alpha Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alpha Biopharma in its N-PORT filings yet. We sweep new filings monthly.